Cantor Fitzgerald Reiterates Overweight on Immunovant, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Immunovant (NASDAQ:IMVT) and maintained a $30 price target.
August 22, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Immunovant and maintained a $30 price target, indicating a positive outlook for the company.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates that the analyst believes Immunovant's stock will outperform the market in the future. The maintained price target of $30 suggests that the analyst sees potential for the stock's price to increase, which could positively impact the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100